• In management commentary for the three and six months ended June 30, 2026, revenue fell to USD 11.72 million from USD 14.8 million.
• Lower online sales volumes drove the decline, reflecting challenging market conditions despite portfolio and marketing initiatives.
• Gross profit margin rose 1.2% for the six-month period, attributed to supply-chain optimization and cost savings.
• Net loss widened to USD 1.04 million from USD 544,000, reflecting weaker revenue and higher general and administrative expense.
• Cash was USD 6.4 million; working capital was USD 8.38 million, down from USD 9.47 million at year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innocan Pharma Ltd. published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.